Novavax Says Omicron Shot Meets Number one Pressure-Exchange Endpoint in Overdue-Degree Trial



MT Newswires 2022

All information about NOVAVAX, INC.

Analyst Tips on NOVAVAX, INC.

Gross sales 2022 2 011 M

Web source of revenue 2022 -8,35 M

Web money 2022 1 455 M

P/E ratio 2022 -134x
Yield 2022
Capitalization 1 520 M
1 520 M
EV / Gross sales 2022 0,03x
EV / Gross sales 2023 0,03x
Nbr of Staff 1 541
Loose-Glide 98,8%



Period :


Duration :




Novavax, Inc. Technical Analysis Chart | MarketScreener

Technical research traits NOVAVAX, INC.

Quick Time period Mid-Time period Lengthy Time period
Developments Bullish Bearish Bearish




Source of revenue Remark Evolution

Promote

Purchase

Imply consensus OUTPERFORM
Collection of Analysts 6
Ultimate Shut Value 19,43 $
Reasonable goal worth 81,33 $
Unfold / Reasonable Goal 319%



Verepass helps sort through the science of COVID-19, process it, and offer an easy pathway to understanding your COVID-19 health, which will get you back to doing what you enjoy.